Progress in drug delivery: SAINT-O-Somes
Synvolux has a long-standing experience in the formulation and production of transfection reagents for macromolecules such as DNA, RNA, and proteinaceous material.
SAINT-O-Somes, invented by Synvolux and patent-pending, allow the targeted delivery of biomolecules in vitro and in vivo to specific cell types or tissues. For example, SAINT-O-Somes targeted to VCAM-1 and E-selectin have been demonstrated to selectively and functionally deliver siRNA into inflammation-activated endothelial cells in vitro. What’s more, Kowalski et al. demonstrated endothelial-cell-specific delivery of siRNA by targeted Anti-VCAM-1 SAINT-O-Somes in vivo, resulting in downregulation of inflammatory genes in inflamed mouse kidney.
This new class of synthetic drug-delivery devices is biodegradable, targetable and biocompatible. Targeted SAINT-O-Some technology may significantly reduce clinical effective dosing, minimize off-target effects, and thereby reducing adverse effects in patients. For more information on how SAINT-O-Somes are or can be used, feel free to contact us.
Synvolux Therapeutics is continuing its effort to make resources available to bring targeted drug delivery technology towards a relevant clinical application. Since SAINT-O-Somes provide a platform technology and possibilities are numerous, researchers with co-development proposals are invited to share ideas.